MFN News Items | Nanologica

NOTICE CONVENING THE ANNUAL GENERAL MEETING OF NANOLOGICA AB (PUBL)

16 April, 2025

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby summoned to the Annual General Meeting on Thursday 22 May 2025, at 12.00 CET, at Advokatfirman Lindahl’s premises at Smålandsgatan 16, Stockholm. English translation for information purposes only. If there are differences between the English translation and the Swedish original, the Swedish text will take precedence. Right to attend the meeting Shareholders who wish to participate in the Annual General Meeting must: be

KALLELSE TILL ÅRSSTÄMMA I NANOLOGICA AB (PUBL)

16 April, 2025

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till årsstämma torsdagen den 22 maj 2025, klockan 12.00, i Advokatfirman Lindahls lokaler på Smålandsgatan 16, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i årsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken onsdagen den 14 maj 2025, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast fredagen den 16 maj

Interim Report Q1 2025 Nanologica AB (publ)

16 April, 2025

FINANCIAL SUMMARY Net sales for the first quarter amounted to SEK 10,751 thousand (5,037) The operating loss amounted to SEK 9,241 thousand (15,331) Loss after tax amounted to SEK 10,171 thousand (16,734) Earnings per share before and after dilution were SEK -0.12 (-0.46) Cash and cash equivalents per 31 March 2024 amounted to SEK 28,348 thousand (23,600). Shortly after the end of the quarter, the company's cash and cash equivalents increased by approximately SEK 7

Delårsrapport Q1 2025 Nanologica AB (publ)

16 April, 2025

FINANSIELL SAMMANFATTNING Nettoomsättningen för första kvartalet uppgick till 10 751 TSEK (5 037) Rörelseresultatet uppgick till -9 241 TSEK (-15 331) Resultatet efter skatt uppgick till -10 171 TSEK (-16 734) Resultat per aktie före och efter utspädning var -0,12 SEK (-0,46) Likvida medel uppgick per den 31 mars 2025 till 28 348 TSEK (23 600). Strax efter kvartalets utgång ökades bolagets likvida medel med ca 7 MSEK till följd av inkommande betalning från kund.

NANOLOGICA AB CHANGES DATES FOR INTERIM REPORT

15 April, 2025

Nanologica’s interim report for the first quarter will be published on April 16 instead of April 17. The report will be published on the company’s website at approx. 08.10. For further information, please contact:Johanna Johansson, Director IR, Communications and Marketing Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com About Nanologica AB (publ)Nanologica is a Swedish life science tools company that develops, manufactures and sells advanced consumables to pharmaceutical companies. Nanologica's silica-based products are specially developed

NANOLOGICA AB ÄNDRAR DATUM FÖR DELÅRSRAPPORT

15 April, 2025

Nanologicas delårsrapport för första kvartalet publiceras 16 april istället för 17 april. Rapporten publiceras på bolagets hemsida ca 08.10. För ytterligare information, vänligen kontakta:Johanna Johansson, Director IR, Communications and Marketing Tel: +46 72 211 21 90 eller e-post: ir@nanologica.com Om Nanologica AB (publ)Nanologica är ett svenskt life science tools-bolag som utvecklar, tillverkar och säljer avancerade insatsvaror till läkemedelsproducerande företag. Nanologicas silikabaserade produkter är speciellt framtagna för rening av peptidläkemedel, såsom insulin och GLP-1-analoger. Tack vare att

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.